Inactive Instrument

Boston Therapeutics Inc Stock OTC Bulletin Board

Latest news : Boston Therapeutics Inc

25/11/23	Nanomix Corporation Announces Chief Executive Officer Changes	CI
07/04/23	Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
07/04/23	Nanomix Corporation Auditor Raises 'Going Concern' Doubt	CI
25/01/23	Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial Officer	CI
29/11/22	Nanomix Corporation Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy	CI
15/11/22	Nanomix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
09/11/22	Nanomix Corporation Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd	CI
09/11/22	Nanomix Corporation announced that it has received $0.069779 million in funding from Woodley Equipment Company Ltd.	CI
04/11/22	Nanomix Corporation Enters into Multi-Country Distribution Agreement for the Elab System with Mast Group Limited	CI
20/10/22	Nanomix Corporation Announces Distribution Agreement with Diaclinic SpA	CI
12/09/22	Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Ips Genomix S.A.L. in the Middle East	CI
02/09/22	Nanomix Corporation Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies	CI
31/08/22	Nanomix Names Tadd S. Lazarus to Board of Directors	CI

More news

Press Releases: Boston Therapeutics Inc

13/04/23	Nanomix Announces Equity Investment from Senior Executive of Woodley Equipment Company, Ltd. at a Premium to Market	GL
07/04/23	NANOMIX CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
11/03/23	NANOMIX CORP : Regulation FD Disclosure (form 8-K)	AQ
26/01/23	NANOMIX CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
25/01/23	Nanomix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer	GL

More press releases

Boston Therapeutics, Inc. (BTI) is a pre-clinical and clinical-stage pharmaceutical company. The Company is focused on the development, manufacture and commercialization of carbohydrate-based therapeutic drugs and dietary supplements designed to address blood sugar management and inflammatory diseases. BTI-320 is its lead product candidate. BTI-320 is a Carbohydrate hydrolyzing Enzyme Inhibitor for treatment of patients with Type 2 diabetes. BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications, which is designed to reduce post-meal glucose elevation. BTI-320 is in Phase II clinical development. IPOXYN and OXYFEX are in pre-clinical stage of drug development. IPOXYN is indicated for lower limb vascular complications of diabetes. OXYFEX is indicated for veterinary ischemic tissue. It produces and sells SUGARDOWN, a non-systemic carbohydrate-based dietary food supplement to support post-meal blood glucose.

Employees

Sector

More about the company